RPS15A

Small ribosomal subunit protein uS8 · P62244 · RPS15A on Sugi Atlas →

3,411 patent compounds predicted against RPS15A, 1,735 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13625506	0.44	7/20
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Geneticin (SCHEMBL13970238)	0.93	1/20

Clinical trials — most relevant to RPS15A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection	PHASE2	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Mitoquines in COPD	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPS15A binder may also engage these)

Protein	Name	Similarity
G1TG89	—	1.000	G1TG89 →
P62246	—	1.000	P62246 →
Q76I82	—	1.000	Q76I82 →
P62245	—	1.000	P62245 →
Q6Q420	—	1.000	Q6Q420 →
Q5R938	—	0.997	Q5R938 →
Q90YQ8	—	0.991	Q90YQ8 →
P42798	—	0.954	P42798 →
P42794	—	0.949	P42794 →
Q9AT34	—	0.948	Q9AT34 →
Q00332	—	0.948	Q00332 →
A2YDY2	—	0.946	A2YDY2 →
Q0DK10	—	0.944	Q0DK10 →
P50894	—	0.943	P50894 →
Q9LX88	—	0.943	Q9LX88 →
P04644	—	0.942	P04644 →
P62084	—	0.942	P62084 →
RPS17	Small ribosomal subunit protein eS17	0.942	landscape →
P46287	—	0.942	P46287 →
P42795	—	0.940	P42795 →
Q90YR7	—	0.940	Q90YR7 →
Q9CZX0	—	0.940	Q9CZX0 →
G1TU13	—	0.940	G1TU13 →
A5PK63	—	0.940	A5PK63 →
G1TSG1	—	0.940	G1TSG1 →
P62250	—	0.939	P62250 →
Q4R5I3	—	0.938	Q4R5I3 →
Q9H9T3	—	0.938	Q9H9T3 →
Q90YQ6	—	0.938	Q90YQ6 →
P63276	—	0.937	P63276 →